Medigen Vaccine Biologics (6547.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0006547003

Price
46.40 TWD
Market cap
15.25 bn TWD
P/E (2025)
–
P/S (2025)
24.88
Dividend yield
0.00 %
Net margin
-45.94 %
Return on equity (ROE)
-8.10 %
Return on assets (ROA)
-7.16 %

Medigen Vaccine Biologics financials

Fiscal year20242025
Revenue605.64 m TWD613.17 m TWD
Gross profit396.42 m TWD364.67 m TWD
Operating income-145.67 m TWD-265.69 m TWD
EBIT-61.58 m TWD-272.91 m TWD
Net income-80.47 m TWD-281.71 m TWD
Diluted EPS – continuing operations-0.24 TWD-0.86 TWD

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.